Assessment of interleukins 1 and 6 in hypertensive subjects

A.O. OLUBOYO*, C.M. OKORO, V.E. EKPO and B.O. OLUBOYO

Department of Medical Laboratory Science, College of Medicine and Health Sciences, Afe Babalola University, Ado Ekiti, Ekiti State, Nigeria.

*Corresponding author; E-mail: oluboyoao@abuad.edu.ng; Tel: +2348062549343

ABSTRACT

Hypertension has been the most frequent non-communicable disease and the most routinely diagnosed cardiovascular disorder in Nigeria. It has been linked to various diseases and complications. Therefore, the study assessed interleukin (IL) 1, 6 and anthropometric parameters in hypertensive subjects. A total of ninety subjects were investigated; thirty hypertensive subjects on antihypertensive therapy, thirty hypertensive subjects not on therapy and thirty control subjects without hypertension. Blood pressure was measured using sphygmomanometer (Omros, Japan) while body mass index (BMI) was determined by using the formula: weight/height (kg/m²). Interleukin 1 and 6 were determined using enzyme linked immunosorbent assay (ELISA) technique. The systolic blood pressure, diastolic blood pressure, IL-1 was significantly higher (P<0.05) in hypertensive subjects on antihypertensive agents and those not on antihypertensive agents compared with the control. There was no significant correlation between IL-1, IL-6 and anthropometric parameters (P>0.05) but IL-1 was significantly increased in females compared with male subjects. The study concluded that IL-1 and IL-6 are increased during hypertension. Thus, the parameters may be used in the assessment and monitoring of cases of hypertension so as to prevent development of inflammatory conditions in hypertensive subjects.

© 2019 International Formulae Group. All rights reserved.

Key words: IL-1, IL-6, blood pressure, BMI, hypertension.

INTRODUCTION

Hypertension (HTN) is a global problem which affects about 40% of the world’s population and has been estimated to be the cause of a large part of death from cardiovascular diseases (Chamarthi et al., 2011; Howard et al., 2014). Worldwide hypertension is estimated to cause 7.5 million deaths and about 12.8% of the total deaths (Lim et al., 2012). In 2010 hypertension was believed to have been a factor in 18% of all deaths (9.4 million globally) (Campbell et al., 2015).

Hypertension and its complications form a large percentage of urgent medical admissions in urban hospitals in Nigeria (Akinlua et al., 2015; Ajayi et al., 2016). Hypertension is the most paramount modifiable risk factor for cardiovascular disease (Novo et al., 2009). The causes of hypertension are multifactorial and cut across every social class (Ghogomu et al., 2016; Norbert et al., 2017). Hypertension is linked with various diseases such as cardiovascular disease, hyperuricidemia, carbohydrate intolerance, renal failure and many more...
It usually occurs as a result of environmental and genetic factors or an interaction between both factors (Poulter et al., 2015). Risk factors of primary hypertension include excessive intake of dietary salt, overweight, smoking, and alcohol use (Ma et al., 2015; Poulter et al., 2015; CDC, 2019).

In the immune system, the production of IL-1 is in most cases induced, generally resulting in inflammation. IL-1 is extremely produced by tissue macrophages, monocytes, fibroblasts, and dendritic cells, but is also exhibited by B lymphocytes, natural killer (NK) cells, microglia, and epithelial cells (Duque and Descoteaux, 2014; Yan et al., 2019). They form a major part of the inflammatory response of the body against infection. Interleukin 6 (IL-6) is a pleiotropic cytokine with a broad range of biologic activities in control of immunological process, production of blood cells, inflammation, and formation of cancerous cells (Tanase et al., 2019). IL-1 also induces its own production and processing which is key in the pathogenesis of many auto inflammatory diseases (Dinarello, 2012; Doria et al., 2012).

Inflammatory mediators play key roles in atherosclerosis, from initial leukocyte recruitment through rupture of the atherosclerotic plaque (Petrella, 2010). Inflammation is also an early event in cardiac stress as elevated levels of endothelial adhesion molecules and increased inflammatory cytokine and chemokine production or release are observed in affected cardiac tissues (Glezeva et al., 2014). Interleukin-6 is a classic pro-inflammatory cytokine needed to mount an effective immune response. It seems that interleukin-6 has an important role in the dynamic and superbly orchestrated process of innate immunity after myocardial infarction. Interleukin-6 timely suppresses innate immune signals to prevent the catastrophic consequences of uncontrolled inflammation on cardiac geometry and function, and thus tunes myocardial remodeling (Huang et al., 2015). Therefore, the study assessed interleukin 1 and 6 in hypertensive subjects to determine whether there are alterations in the levels of these inflammatory cytokines since there is involvement of inflammatory processes in hypertensive subjects.

**MATERIALS AND METHODS**

This research was conducted in Federal Teaching Hospital, Ido-Ekiti, Ekiti State, Nigeria. All sample analysis was carried out in the laboratory of the Medical Laboratory Science Department, Afe Babalola University. Ethical approval was sought for and obtained from Federal Teaching Hospital, Ido-Ekiti, Ekiti State. The nature and purpose of research was explained to each participant using an informed consent form for literate participants and verbal explanation for illiterate participants. Participants were not forced to answer questions but at their free will. The participants were ensured of confidentiality and voluntary participation but were told that there is no financial benefit whatsoever. This study included ninety subjects; sixty hypertensive subjects out of whom thirty subjects were on anti-hypertensive therapy and thirty apparently healthy subjects without hypertension (control subjects). The study did not involve subjects below 18 years, pregnant women, nursing mothers, diabetes mellitus subject and other disease conditions.

Weight and height of subjects were measured using a bathroom scale and a height gauge (Pasco scale co., Ltd, India). Body mass index (BMI) was determined by using the formula: weight/height (kg/m²). Blood pressure was taken from the non-dominant arm using appropriate cuff size and mercury sphygmomanometer (Omros, Japan). Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were the first and fifth korokoff sounds respectively. Venous blood sample of about five milliliters (5ml) was collected from the subjects for the analysis of interleukin 1 and 6 using ELISA technique purchased from Melsin Medical Co., Limited, China.
Statistical Analysis
The data obtained were subjected to statistical analysis using Statistical Package for Social Sciences version 23 (version 23.0 software, SPSS Inc. Chicago, Illinois, USA). All parameters were expressed as mean ± standard deviation (SD). Student ’t’ test was the tool of choice and values were found to be statistically significant at p<0.01 or p<0.05.

RESULTS
Table 1 shows the mean ± SD of BMI, blood pressure, IL-1 and IL-6 in hypertensive subjects on antihypertensive agent, those not on antihypertensive agents and control. The systolic blood pressure, diastolic blood pressure, IL-1 were significantly higher (P<0.05) in hypertensive subjects on antihypertensive agents and those not on antihypertensive agents compared with the control group. IL-6 was significantly lower in hypertensive subjects on antihypertensive agent but high in those not on antihypertensive agents compared with control. The BMI was not significantly higher in hypertensive subjects compared with the control group.

Table 2 shows the relationship between the parameters in hypertensive subjects. It shows that there was positive significant correlation between systolic and diastolic blood pressure at p<0.05 but there was no significant correlation between IL-1, IL-6 and anthropometric parameters.

Figure 1 shows anthropometric parameters, IL-1 and IL-6 in hypertensive subjects according to gender. Systolic BP was significantly higher in males compared with females whereas IL-1 was significantly increased in females compared with male subjects.

Table 1: Anthropometric parameters, interleukin 1 and 6 in hypertensive and control subjects.

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Hypertensives on treatment N=30</th>
<th>Hypertensives not on treatment N=30</th>
<th>Control N=30</th>
<th>F-values</th>
<th>P-values</th>
</tr>
</thead>
<tbody>
<tr>
<td>BMI (Kg/m²)</td>
<td>29.44±5.65</td>
<td>28.14±4.29</td>
<td>27.38±4.86</td>
<td>1.382</td>
<td>0.257</td>
</tr>
<tr>
<td>Systolic Bp (mmHg)</td>
<td>145.93±15.81</td>
<td>152.10±12.84</td>
<td>107.73±10.40</td>
<td>99.362</td>
<td>0.000**</td>
</tr>
<tr>
<td>Diastolic Bp (mmHg)</td>
<td>86.87±15.79</td>
<td>93.73±10.97</td>
<td>68.83±8.80</td>
<td>33.258</td>
<td>0.000**</td>
</tr>
<tr>
<td>IL-1 (Pg/mL)</td>
<td>17.65±12.57</td>
<td>20.65±4.65</td>
<td>12.16±2.76</td>
<td>8.925</td>
<td>0.000**</td>
</tr>
<tr>
<td>IL-6 (Pg/mL)</td>
<td>8.84±1.86</td>
<td>15.96±10.60</td>
<td>10.00±5.65</td>
<td>8.897</td>
<td>0.000**</td>
</tr>
</tbody>
</table>

Where
** Significant levels at P<0.05
BMI = body mass index
Bp = Blood pressure
Kg/m² = Kilogram / meter²
mmHg = millimetre of mercury
Pg/mL = picogram / milliliter.
Table 2: Correlation of Interleukin 1 and 6 with other parameters in hypertensive Subjects.

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Correlations (R) / P values</th>
<th>Systolic Bp</th>
<th>Diastolic Bp</th>
<th>BMI</th>
<th>IL-1</th>
<th>IL-6</th>
</tr>
</thead>
<tbody>
<tr>
<td>Systolic Bp</td>
<td>R</td>
<td>1.000</td>
<td>0.326*</td>
<td>-0.049</td>
<td>-0.075</td>
<td>-0.007</td>
</tr>
<tr>
<td></td>
<td>P</td>
<td>-</td>
<td>0.011</td>
<td>0.707</td>
<td>0.570</td>
<td>0.956</td>
</tr>
<tr>
<td>Diastolic Bp</td>
<td>R</td>
<td>0.326*</td>
<td>1.000</td>
<td>-0.097</td>
<td>0.052</td>
<td>0.042</td>
</tr>
<tr>
<td></td>
<td>P</td>
<td>0.011</td>
<td>-</td>
<td>0.463</td>
<td>0.691</td>
<td>0.752</td>
</tr>
<tr>
<td>BMI</td>
<td>R</td>
<td>-0.049</td>
<td>-0.097</td>
<td>1.000</td>
<td>-0.097</td>
<td>-0.140</td>
</tr>
<tr>
<td></td>
<td>P</td>
<td>0.707</td>
<td>0.463</td>
<td>-</td>
<td>0.461</td>
<td>0.287</td>
</tr>
<tr>
<td>IL-1</td>
<td>R</td>
<td>-0.075</td>
<td>0.052</td>
<td>-0.097</td>
<td>1.000</td>
<td>0.080</td>
</tr>
<tr>
<td></td>
<td>P</td>
<td>0.570</td>
<td>0.691</td>
<td>0.461</td>
<td>-</td>
<td>0.542</td>
</tr>
<tr>
<td>IL-6</td>
<td>R</td>
<td>-0.007</td>
<td>0.042</td>
<td>-0.140</td>
<td>0.080</td>
<td>1.000</td>
</tr>
</tbody>
</table>

* significant levels at P<0.05.

Figure 1: Anthropometric parameters, IL-1 and IL-6 in hypertensive subjects according to gender.
DISCUSSION

In this study, systolic and diastolic blood pressures of hypertensive subjects were assessed and compared between the hypertensive subjects and control (Table 1). The systolic and diastolic blood pressures were found to be significantly higher in hypertensive subjects compared with control. This research agrees with the works of Oluboyo et al. (2018); Odewusi and Osadolor (2019) where systolic and diastolic blood pressures were seen to be significantly higher in hypertensive subjects compared with control. There was also a significant increase in systolic blood pressure of the males when compared with the female subjects.

Body mass index (BMI) was also assessed and compared between the hypertensive subjects compared with control in this study. The BMI of hypertensive subjects on therapy and those not on therapies were higher but not statistically significant when compared with control subjects. This supports the works of Zhang et al. (2016) and Norbert et al. (2017) where increased BMI has been associated with hypertension. This research also agrees with the work of Yeldu et al. (2018) where body composition variables such as weight, skin fold thickness and others have been shown to be significantly correlated with blood pressure in adults.

In this study, IL-1 was significantly higher in hypertensive subjects compared with control. This probably may be as a result of its role as a powerful inducer of the innate immune response (Dinarello et al., 2012). IL-1 is considered to be an “early-response” cytokine, involved in energy homeostasis and inflammation, connected to metabolism mechanisms (Erion et al., 2014). There was also a significant increase in IL-6 of hypertensive subjects not on therapy compared with those on therapy and control subjects. IL-6 has been shown to be a proinflammatory cytokine produced by various cells including macrophages, endothelial cells and vascular smooth muscle cells. It is an early regulator of inflammation, which plays a critical role in driving the chronic inflammatory process (Barnes et al., 2011; Mao et al., 2017). IL-6 is the major proinflammatory cytokine and has been described to be linked with hypertension and atherosclerosis (Tanase et al., 2019). This finding agrees with the reports of Gibas-Dorna et al. (2015) where individuals with hypertension were reported to have higher levels of IL-6 compared with control subjects. There was no significant correlation between IL-1, IL-6 and other parameters in the hypertensive subjects (Table 2). The findings of significant increase in IL-1 and IL-6 show that there is involvement of inflammatory processes and immune response in hypertensive subjects. Although, the use of anti-hypertensive agents may regulate the inflammatory process since low level of IL-6 was observed in hypertensive subjects on therapy.

This study also found that a higher number of hypertensive subjects were females. This finding is in agreement with the report of Everett and Zajacova (2015) where it was reported that the rate of hypertension is higher in females than males (Figure 1). However, systolic blood pressure was found to be significantly higher in men compared with women while BMI was higher in females but not significant. This observation is in line with the findings of Akili et al. (2014) where females were found to have a higher body mass index than males. There was significant increase in IL-1 of female hypertensive subjects compared with male hypertensives while there was no significant increase in IL-6 of the male subjects compared with female hypertensive subjects. This partly supports the findings of Gibas-Dorna et al. (2015) which shows that IL-6 is raised in men. There was no significant correlation when IL-1 and IL-6 were compared with other parameters in the hypertensive subjects.
Conclusion
This study concluded that IL-1 and IL-6 were increased in hypertensive subjects, although there was no significant correlation between IL-1 and IL-6 compared with other parameters. Thus, IL-1 and IL-6 may be used in the assessment and monitoring of cases of hypertension so as to prevent development of inflammatory conditions in hypertensive subjects.

COMPETING INTERESTS
The authors declare that there is no competing interest.

AUTHORS’ CONTRIBUTIONS
AOO and BOO were responsible for the project design, survey, statistical calculations, writing and editing of the manuscript. CMO and VEE were responsible for experimental analysis, scientific and conceptual contributions to the manuscript.

ACKNOWLEDGEMENTS
The Authors acknowledge the support of the staff members of Chemical Pathology Laboratory of Federal Medical Center, Ido Ekiti, Ekiti State for their support during sample collection.

REFERENCES


